Javier Morales, MD, FACP, FACE; David Robertson, MD; Andrea Stallings, PA, and Shira Eytan, MD, FACE, examine the comprehensive burden of Type 1 diabetes, from screening guidelines and disease staging to the critical importance of early intervention, emphasizing how delayed treatment in Stage 2 can lead to severe complications and diminished therapeutic opportunities.
Javier Morales, MD, FACP, FACE; Shira Eytan, MD, FACE; Bethany Kinsey, NP; Quentin Van Meter, MD, and David Robertson, MD, discuss the progression and management of Type 1 diabetes, from early screening protocols through disease stages and intervention timing, emphasizing the critical importance of vigilant monitoring and prompt treatment to prevent severe complications.
Panelists discuss how early screening, timely intervention with teplizumab, and a proactive, multidisciplinary approach can significantly delay the progression of type 1 diabetes (T1D) and improve patient outcomes.
Panelists discuss how early screening, timely intervention, and the use of teplizumab can improve outcomes for individuals with type 1 diabetes (T1D) by delaying disease progression and reducing complications like diabetic ketoacidosis.
